Aldeyra Therapeutics Inc
ALDX
View Detailed Chart
5.010USD
+0.110+2.24%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
300.83MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.24%
5 Days
-9.89%
1 Month
-7.90%
6 Months
-24.83%
Year to Date
+0.40%
1 Year
-14.65%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
9.500
Target Price
+91.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Fairly Valued
The company’s latest PE is -5.78, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.94M shares, decreasing 17.64% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.50M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.24.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Ticker SymbolALDX
CompanyAldeyra Therapeutics Inc
CEODr. Todd C. Brady, M.D., Ph.D.
Websitehttps://www.aldeyra.com/
Related Instruments
-0.35%
-4.12%
+3.22%
+1.88%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+2.93%
+0.93%
+5.59%
+3.22%
0.00%
+2.85%
